CoChat

Comparison of monoclonal antibody disposition predictions using different physiologically based pharmacokinetic modelling platforms

Open access
De Sutter, Pieter-Jan, Gasthuys, Elke, Vermeulen, An · 2024 · Journal of Pharmacokinetics and Pharmacodynamics

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

Physiologically based pharmacokinetic (PBPK) models can be used to leverage physiological and in vitro data to predict monoclonal antibody (mAb) concentrations in serum and tissues. However, it is currently not known how consistent predictions of mAb disposition are across PBPK modelling platforms. In this work PBPK simulations of IgG, adalimumab and infliximab were compared between three platforms (Simcyp, PK-Sim, and GastroPlus). Accuracy of predicted serum and tissue concentrations was assessed using observed data collected from the literature. Physiological and mAb related input parameters were also compared and sensitivity analyses were carried out to evaluate model behavior when input values were altered. Differences in serum kinetics of IgG between platforms were minimal for a dose of 1 mg/kg, but became more noticeable at higher dosages (> 100 mg/kg) and when reference (healthy) physiological input values were altered. Predicted serum concentrations of both adalimumab and infliximab were comparable across platforms, but were noticeably higher than observed values. Tissue concentrations differed remarkably between the platforms, both for total- and interstitial fluid (ISF) concentrations. The accuracy of total tissue concentrations was within a three-fold of observed values for all tissues, except for brain tissue concentrations, which were overpredicted. Predictions of tissue ISF concentrations were less accurate and were best captured by GastroPlus. Overall, these simulations show that the different PBPK platforms generally predict similar mAb serum concentrations, but variable tissue concentrations. Caution is therefore warranted when PBPK models are used to simulate effect site tissue concentrations of mAbs without data to verify the predictions.

Overview

CoChat Summary

TL;DR

This paper compares monoclonal antibody disposition predictions across three PBPK platforms—Simcyp, PK-Sim, and GastroPlus—for IgG, adalimumab, and infliximab. The platforms gave broadly similar serum predictions but substantially different tissue predictions, so the authors caution against using tissue-effect-site predictions without verification.

Key findings

  • For IgG, serum kinetics were “minimal” across platforms at 1 mg/kg, but differences became more noticeable at doses >100 mg/kg and when healthy reference physiological inputs were altered.
  • Predicted serum concentrations of adalimumab and infliximab were comparable across platforms, but were “noticeably higher” than observed values.
  • Tissue concentrations differed “remarkably” across platforms for both total tissue and interstitial fluid (ISF) concentrations.
  • Total tissue concentration predictions were within a three-fold of observed values for all tissues except brain, which was overpredicted; ISF predictions were less accurate and were best captured by GastroPlus.

Methods

  • Comparative PBPK simulation study across three modeling platforms: Simcyp, PK-Sim, and GastroPlus.
  • Simulated IgG, adalimumab, and infliximab using physiological and mAb-related input parameters; observed serum and tissue data were collected from the literature for comparison.
  • Performed sensitivity analyses to evaluate model behavior when input values were altered.

Limitations

  • Stated by the paper: prediction accuracy for tissue ISF concentrations was lower than for total tissue concentrations, and these were only “best captured by GastroPlus.”
  • Stated by the paper: caution is warranted when PBPK models are used to simulate effect-site tissue concentrations of mAbs without data to verify the predictions.
  • Evident from the text: the study relies on observed data collected from the literature rather than a single standardized experimental dataset, which may limit direct comparability across outputs.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s10928-023-09894-4

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 Valid · 0 Not valid · 0 Not checked · 17 Own results and interpretations

10 more claims

Create a free account to see all 17 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 2

Create a free account to see these claims.

Citations

Cites

Show all 34 references

Research works printed but not linked: 1

  1. den Broeder A, van de Putte L, Rau R et al (2002) A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol 29:2288–2298

Cited by

See all 8

Metadata

Authors
De Sutter, P.-J., Gasthuys, E., & Vermeulen, A.
Affiliations
Ghent University (BE)
Venue
Journal of Pharmacokinetics and Pharmacodynamics
Published
2023-11-12
Volume
51
Issue
6
Pages
639-651
ISSN
  • 1567-567X (ISSN-L)
  • 1573-8744
OpenAlex
W4388603732
Cited by
8
References
34
Citations by year
2026: 4 · 2025: 3 · 2024: 1
FWCI
1.32
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Pharmacokinetics and Pharmacodynamics (publishedVersion)
  • PubMed (publishedVersion)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
Keywords
monoclonal antibodies, physiologically based pharmacokinetic modeling, adalimumab, infliximab, IgG, tissue distribution, brain tissue concentration, SimCYP, PK-Sim, GastroPlus, sensitivity analysis
MeSH terms
Adalimumab, Infliximab, Antibodies, Monoclonal, Computer Simulation, Humans, Immunoglobulin G, Models, Biological, Tissue Distribution

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparison of monoclonal antibody disposition predictions using different physiologically based pharmacokinetic modelling platforms. https://app.cochat.ai/papers/10.1007/s10928-023-09894-4
The paper
De Sutter, P.-J., Gasthuys, E., & Vermeulen, A. (2024). Comparison of monoclonal antibody disposition predictions using different physiologically based pharmacokinetic modelling platforms. Journal of Pharmacokinetics and Pharmacodynamics. https://doi.org/10.1007/s10928-023-09894-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.